Published in Blood Weekly, June 9th, 2005
"Prostate cancers are genetically and phenotypically heterogenous. The heterogeneous nature of prostate cancer may be a consequence of mutations in different cell types (basal stem, transit amplifying or luminal cells) resulting in different malignant maturation pathways.
"One consistent characterization of these cancers, however, is their eventual progression to a hormonal refractory state," scientists in the United States report.
"The development of effective novel therapeutic strategies requires an understanding of the mechanisms...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.